Equitable (EQH) Q2 2025 Earnings Transcript

Equitable reported Q2 non-GAAP operating earnings of $352 million, or $1.10 per share, down 23% year over year, but management highlighted a major positive: the July RGA reinsurance deal freed over $2 billion of capital and cut mortality exposure by 75%. Assets under management and administration hit a record $1.1 trillion, retirement net inflows were $1.9 billion, and wealth advisory net inflows reached $2 billion, offsetting $6.7 billion of AB outflows. Management expects EPS growth to accelerate in the second half, plans at least $500 million of incremental buybacks, and reiterated a 2027 target of $2 billion in annual organic cash generation.

Analysis

EQH is transitioning from a volatility story to a capital-allocation story, and that is the key second-order shift. Once the mortality overhang is mechanically reduced, the market is likely to re-rate the name less on headline EPS and more on the durability of distributable cash flow and buyback capacity; that supports a multiple expansion even if near-term reported growth remains noisy. The balance-sheet reset also matters for equity holders because the freed capital can be recycled into higher-ROE assets faster than the earnings drag from the ceded block, creating a cleaner compounding profile over the next 4-8 quarters.

The bigger winner may be AB, not just EQH. Higher ownership, more insurance mandates, and a deeper spread-lending pipeline should structurally improve AB’s earnings mix, while the private-markets build and insurance-general-account relationships are effectively a distribution channel into sticky capital. That said, the same flywheel can become a source of disappointment if active flows at AB remain weak; the market will tolerate cyclical outflows only if the fee base from insurance and alternatives keeps offsetting it.

The underappreciated risk is that management is leaning on market recovery to justify a second-half acceleration, so the trade is vulnerable if rates back up, equities stall, or mortality normalizes less quickly than assumed. Another subtle issue: the RILA book is becoming more mature, so future growth in account value may not translate one-for-one into earnings if legacy high-margin runoff persists longer than expected. That creates a path dependency where the stock can work on capital returns alone, but the multiple likely stays capped until investors see a clean quarter of both stable mortality and sustained inflows.

Key Decisions for Investors

• Long EQH on a 3-6 month horizon into the post-reinsurance reset; target a rerating driven by a cleaner cash-return profile, with downside capped by the enlarged buyback authorization and capital release. Use pullbacks tied to market weakness as entry points rather than chasing strength.
• Pair trade: long EQH / short a lower-capital-return life insurer with less visible excess capital and more earnings volatility. The spread should favor EQH if management executes even half of the announced repurchase cadence over the next 2 quarters.
• Long EQH common and sell out-of-the-money puts 1-2 quarters out to monetize elevated uncertainty while expressing a view that mortality noise is now largely behind the company. This works best if implied volatility remains elevated versus realized.
• Add AB on weakness, but only as a higher-beta satellite to EQH, not a standalone core long. The thesis is that insurance-related mandates and private markets will offset active flow pressure over the next 6-12 months; if active outflows reaccelerate, trim quickly.
• Avoid shorting EQH here unless you have a strong bearish view on equity markets or mortality trends. The free-cash-flow and capital-return setup creates a favorable asymmetry: any operational miss likely gets cushioned by buybacks, while upside is amplified by multiple expansion.